Authors


Priya K. Gopalan, MD, MPH

Latest:

Caring for Patients With Serious Mental Illness: Guide for the Oncology Clinician

Veronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.


Atif Iqbal, MD, FACS, FACRS

Latest:

Clinical Trials in Progress: COBRA

Phase 2/3 Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA): a first-in-kind trial seeks to provide level 1 evidence in evaluating the role of ctDNA as a guide for clinicians in the decision to administer adjuvant chemotherapy to patients with stage IIA colon cancer (NRG GI-005) (NCT04068103).


Alex Francoeur, MD

Latest:

Ovarian Cancer Palliative Care May Decrease Readmission Rates, Expert Says

The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.


Shilong Wu, MD

Latest:

The Effect of Prior Cancer on Survival of Patients With Thymoma

Shilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.



Shiraj Sen, MD, PhD

Latest:

Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Molecular profiling is being explored in pancreatic adenocarcinoma as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials.


Jeffrey Zonder, MD

Latest:

Cross Q&A: Role of Belantamab Mafodotin in MM

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.


Katie Bruce, PharmD, BCPPS

Latest:

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.


Fernando Sabino Marques Monteiro, MD

Latest:

Use of Immunotherapy in Patients With Cancer During the COVID-19 Pandemic

This article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.




Tiffany Y. Shaw, MD

Latest:

Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer

In recent years, first-line therapies for metastatic renal cell carcinoma (mRCC) have shifted to a combination of immune checkpoint inhibitors or a combination of antiangiogenesis tyrosine kinase inhibitors (TKIs) and immunotherapy. This has led to a need to address standard-of-care treatment in the second-line setting.


Lisa J. States, MD

Latest:

Comfort in Whole-Body MRI Testing May Ease Anxiety in LFS Population

Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.


Alok A. Khorana, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Gino Cioffi, MPH

Latest:

The Negative Impact of the COVID-19 Pandemic on Oncology Care at an Academic Cancer Referral Center

COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.


Allison M. Cushman-Vokoun, MD, PhD

Latest:

Mucinous Adenocarcinoma of the Appendix With Histologic Response to Neoadjuvant Chemotherapy: Review of Histologic and Clinical Spectrum of Epithelial Neoplastic Mucinous Lesions of the Appendix

Mehmet Sitki Copur, MD, and colleagues examine the case of a 65-year-old patient with appendiceal mucinous neoplasms of the appendix who was treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.



Tara J. Ghalambor, BS

Latest:

Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review

This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.


Millie Das, MD

Latest:

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.


Michael Schweizer, MD

Latest:

Expert Discusses Bipolar Androgen Therapy Plus PARP Inhibition for Castration-Resistant Prostate Cancer

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.


Vera von Dossow, MD

Latest:

Value of Geriatric Assessment in Patients With Genitourinary Carcinoma

This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.




Tian Zhang MD, MHS

Latest:

Future Directions in mHSPC Management: An Evolving Treatment Landscape

Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.


Carl He, MD

Latest:

Multidisciplinary Team Meetings: Barriers to Implementation in Cancer Care

Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.




Ryan W. Jacobs, MD, Atrium Health Levine Cancer Institute

Latest:

Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges

Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.